Oncothyreon Inc (ONTY) 3.60 $ONTY
Endometrial Cancer Therapeutics Pipeline Review, H1 2015 - 35 Companies & 48 Drug Profiles
M2 - Tue Jul 21, 3:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/psfwd9/endometrial) has announced the addition of the "Endometrial Cancer - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Endometrial Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Endometrial Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acceleron Pharma, Inc. - Aeterna Zentaris Inc. - Ariad Pharmaceuticals, Inc. - Arno Therapeutics, Inc. - ArQule, Inc. - AstraZeneca Plc - AVEO Pharmaceuticals, Inc. - BioMarin Pharmaceutical Inc. - Boehringer Ingelheim GmbH - Critical Outcome Technologies Inc. - Daiichi Sankyo Company, Limited - Eisai Co., Ltd. - Esperance Pharmaceuticals, Inc. - Exelixis, Inc. - Farmsintez - Galena Biopharma, Inc. - Genentech, Inc. - Genmab A/S - GlaxoSmithKline Plc - Gradalis Inc. - ImmunoGen, Inc. - Incyte Corporation - Karyopharm Therapeutics, Inc. - Merck & Co., Inc. - Merck KGaA - Millennium Pharmaceuticals, Inc. - Novartis AG - OncoHoldings, Inc. - Oncothyreon Inc. - Otsuka Holdings Co., Ltd. - Pharma Mar, S.A. - Puma Biotechnology, Inc. - Sanofi - Scancell Holdings Plc - Shenogen Pharma Group Ltd. Drug Profiles - (ponatinib hydrochloride ridaforolimus) - ???Pb-TCMC-Trastuzumab - AEZS-125 - afuresertib hydrochloride trametinib dimethyl sulfoxide - ARQ-092 - AV-203 - AZD-2014 - AZD-5363 - buparlisib hydrochloride - cabozantinib s-malate - cancer vaccine - Cell Therapy for Oncology - CLR-457 - COTI-2 - cridanimod - dalantercept - EP-200 - epacadostat - everolimus - FROST-450 - GALE-301 - GDC-0927 - GSK-2636771 - HO-3867 - HuMax-TF-ADC - INCB-54828 - lenvatinib - lurbinectedin - mirvetuximab soravtansine - MK-2206 - Modi-1 - Monoclonal Antibody to Inhibit L1CAM for Ovarian and Endometrial Cancer - neratinib - nintedanib - onapristone ER For more information visit http://www.researchandmarkets.com/research/ps...ndometrial
BMRN: 148.05 (+4.05), ARQL: 1.81 (-0.01), GALE: 1.67 (-0.03), EXEL: 5.88 (-0.43), XLRN: 31.50 (-0.68), INCY: 113.21 (-1.21), IMGN: 18.15 (-0.77), GSK: 42.00 (-0.30), ONTY: 3.60 (-0.03), AZN: 66.55 (-0.67), MRK: 58.07 (-0.06), AVEO: 1.61 (+0.01), PBYI: 98.75 (-1.25), KPTI: 22.95 (-0.26), NVS: 103.05 (+1.75)
Market's Not in the Mood to Move
at The Street - Wed Jul 15, 3:24PM CDT
Attention turns to earnings and away from Greece, Fed.
SGYP: 8.42 (-0.14), BLUE: 163.54 (+1.54), AMBA: 122.99 (+0.49), NFLX: 110.10 (-1.40), EYES: 14.41 (+0.04), AMZN: 482.18 (-6.09), ZIOP: 12.59 (-0.19), LNKD: 224.10 (-0.70), FB: 95.44 (-1.60), RCPT: 228.27 (-0.13), LBIO: 9.47 (-0.42), INTC: 28.59 (-0.01), ONTY: 3.60 (-0.03), CELG: 139.01 (+0.75)
Market Shrugs Off Yellen
at The Street - Wed Jul 15, 12:25PM CDT
She didn't say anything to spook the market, but didn't say anything bullish either.
SGYP: 8.42 (-0.14), BLUE: 163.54 (+1.54), AMBA: 122.99 (+0.49), NFLX: 110.10 (-1.40), EYES: 14.41 (+0.04), AMZN: 482.18 (-6.09), ZIOP: 12.59 (-0.19), LNKD: 224.10 (-0.70), FB: 95.44 (-1.60), RCPT: 228.27 (-0.13), LBIO: 9.47 (-0.42), INTC: 28.59 (-0.01), ONTY: 3.60 (-0.03), CELG: 139.01 (+0.75)
An Excuse for a Little Profit-Taking
at The Street - Wed Jul 15, 9:25AM CDT
The market needs some consolidation after a four-day run.
SGYP: 8.42 (-0.14), BLUE: 163.54 (+1.54), AMBA: 122.99 (+0.49), NFLX: 110.10 (-1.40), EYES: 14.41 (+0.04), AMZN: 482.18 (-6.09), ZIOP: 12.59 (-0.19), LNKD: 224.10 (-0.70), FB: 95.44 (-1.60), RCPT: 228.27 (-0.13), LBIO: 9.47 (-0.42), INTC: 28.59 (-0.01), ONTY: 3.60 (-0.03), CELG: 139.01 (+0.75)
Active Equities to Watch in the Biotechnology Industry -- Prima Biomed, Oncothyreon, Opko Health, ImmunoCellular Therapeutics, and Adaptimmune Therapeutics
PR Newswire - Wed Jul 15, 8:00AM CDT
Equity Research Institute has initiated coverage on the following equities: Prima Biomed Ltd (NASDAQ: PBMD), Oncothyreon Inc. (NASDAQ: ONTY), Opko Health Inc. (NYSE: OPK), ImmunoCellular Therapeutics Ltd (AMEX: IMUC), and Adaptimmune Therapeutics PLC (NASDAQ: ADAP). Free research report on Prima Biomed can be accessed at https://www.EquityResearchInstitute.com/reports?keyword=PBMD On Tuesday, July 14, 2015, the NASDAQ Composite ended at 5,104.89, up 0.66%, the Dow Jones Industrial Average advanced 0.42%, to finish the day at 18,053.58, and the S&P 500 closed at 2,108.95, up 0.45%. The gains were broad based as seven out of nine sectors ended the session in positive. Register for your complimentary reports at the links given below.
PBMD: 1.30 (+0.02), OPK: 17.21 (+0.45), ADAP: 16.59 (-1.08), IMUC: 0.52 (+0.01), ONTY: 3.60 (-0.03)
Market Advances by Playing Small Ball
at The Street - Tue Jun 23, 3:18PM CDT
Not too exciting, but bulls keep chugging along.
AMBA: 122.99 (+0.49), TSLA: 267.20 (-0.67), AMZN: 482.18 (-6.09), EYES: 14.41 (+0.04), FMSA: 5.96 (-0.16), FB: 95.44 (-1.60), EHIC: 12.04 (+0.04), IWM: 123.57 (-1.38), ONTY: 3.60 (-0.03)
Waiting for the Word From Greece
at The Street - Tue Jun 23, 12:32PM CDT
Until something concrete comes out of Greece, don't expect much market action.
AMBA: 122.99 (+0.49), EYES: 14.41 (+0.04), FMSA: 5.96 (-0.16), EHIC: 12.04 (+0.04), IWM: 123.57 (-1.38), ONTY: 3.60 (-0.03)
A Tough Market to Chase
at The Street - Tue Jun 23, 9:50AM CDT
Traders just need a few good movers to feel good about the action.
AMBA: 122.99 (+0.49), EYES: 14.41 (+0.04), FMSA: 5.96 (-0.16), EHIC: 12.04 (+0.04), IWM: 123.57 (-1.38), ONTY: 3.60 (-0.03)
The Trend Says It's a Very Friendly Market
at The Street - Thu Jun 18, 3:26PM CDT
You can find flaws with it, but there isn't money to be gained by fighting its strength.
SGYP: 8.42 (-0.14), EYES: 14.41 (+0.04), FMSA: 5.96 (-0.16), CYBR: 61.72 (+4.22), CCXI: 8.40 (-0.30), EDU: 23.20 (+0.35), MOMO: 16.00 (-0.20), ONTY: 3.60 (-0.03)
Putting Cash to Work
at The Street - Thu Jun 18, 12:33PM CDT
It's the only thing that matters right now.
SGYP: 8.42 (-0.14), EYES: 14.41 (+0.04), FMSA: 5.96 (-0.16), CYBR: 61.72 (+4.22), CCXI: 8.40 (-0.30), EDU: 23.20 (+0.35), MOMO: 16.00 (-0.20), ONTY: 3.60 (-0.03)
Spend Your Energy Finding New Buys
at The Street - Thu Jun 18, 9:35AM CDT
Forget about the macro environment; it's business as usual.
SGYP: 8.42 (-0.14), EYES: 14.41 (+0.04), FMSA: 5.96 (-0.16), CYBR: 61.72 (+4.22), CCXI: 8.40 (-0.30), EDU: 23.20 (+0.35), MOMO: 16.00 (-0.20), ONTY: 3.60 (-0.03)
It's Hard for Market to Make Progress
at The Street - Tue Jun 09, 3:21PM CDT
Stocks bounce back but can't gain traction.
AMBA: 122.99 (+0.49), NFLX: 110.10 (-1.40), EYES: 14.41 (+0.04), DSI: 77.42 (-0.48), AZPN: 44.33 (-0.57), LLY: 86.76 (+0.38), ONTY: 3.60 (-0.03), OHGI: 2.50 (-0.06)
Dip Buying Could Spur Ugly Repercussions
at The Street - Tue Jun 09, 1:25PM CDT
The short-terms aren't worrying about that right now.
EYES: 14.41 (+0.04), DSI: 77.42 (-0.48), AZPN: 44.33 (-0.57), ONTY: 3.60 (-0.03), OHGI: 2.50 (-0.06)
ASCO Event Analyzer - 2015's Winners And Losers
EP Vantage - Seeking Alpha - Thu Jun 04, 1:42PM CDT
Neither Bristol-Myers Squibb (NYSE: BMY ) nor Puma Biotechnology (NYSE: PBYI ) can be scored numerically as the biggest loser coming out of ASCO, but in terms of sentiment, they were neck-and-neck for that title. Both took heavy losses after...
RXDX: 15.60 (-0.71), CLLS: 36.48 (-0.61), CALA: 8.06 (-0.32), IMGN: 18.15 (-0.77), JUNO: 51.65 (-0.12), CTIC: 1.92 (+0.01), BMY: 68.24 (-1.13), ONTY: 3.60 (-0.03), PBYI: 98.75 (-1.25)
Top-Performing Biotech and Drug Stocks During ASCO '15
at The Street - Thu Jun 04, 6:49AM CDT
Between May 12 and June 3, Oncothyreon's stock price rose 183%, best among all the companies presenting cancer drug research at the American Society of Clinical Oncology (ASCO) annual meeting.
RXDX: 15.60 (-0.71), IMGN: 18.15 (-0.77), ONTY: 3.60 (-0.03), PBYI: 98.75 (-1.25)
Dollar General and Delta are big market movers
AP - Tue Jun 02, 3:26PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Tuesday on the New York Stock Exchange and the Nasdaq Stock Market:
DAL: 45.16 (-0.06), ALTR: 49.43 (+0.01), CDTI: 1.80 (+0.01), IMGN: 18.15 (-0.77), HPT: 28.08 (-0.81), BMY: 68.24 (-1.13), ONTY: 3.60 (-0.03), PVH: 114.65 (-0.45), TAOM: 3.16 (unch), APO: 20.70 (-0.51), CBRL: 150.00 (-0.93), DG: 79.82 (-0.59), CTRP: 75.15 (+0.97), ZION: 31.59 (-0.34), TA: 16.00 (-0.23)
My Advice For Young Traders To Successfully Navigate The Market
Brian Nichols - at Seeking Alpha - Tue Jun 02, 9:30AM CDT
ACAD: 49.32 (-0.44), IBM: 161.73 (+1.38), S: 3.67 (-0.14), PG: 80.70 (-0.13), ONTY: 3.60 (-0.03), XPO: 44.11 (-1.96), RAD: 8.79 (-0.04)
Oncothyreon Inc (ONTY) in Focus: Stock Surges 15.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jun 02, 8:21AM CDT
Oncothyreon Inc (ONTY) was a big mover last session, as the company saw its shares surge nearly 16% on the day.
ONTY: 3.60 (-0.03)
Oncothyreon Rises 15.79% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Mon Jun 01, 4:30PM CDT
Oncothyreon (NASDAQ:ONTY) traded in a range yesterday that spanned from a low of $3.78 to a high of $4.69. Yesterday, the shares gained 15.8%, which took the trading range above the 3-day high of $3.66 on volume of 38.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ONTY: 3.60 (-0.03)
Why Shares of Oncothyreon Inc. Shot Up Today
Brian Feroldi, The Motley Fool - Motley Fool - Mon Jun 01, 12:31PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Oncothyreon Inc , a biopharmaceutical...
ONTY: 3.60 (-0.03)
Endometrial Cancer Therapeutics Pipeline Review, H1 2015 - 35 Companies & 48 Drug Profiles
M2 - Tue Jul 21, 3:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/psfwd9/endometrial) has announced the addition of the "Endometrial Cancer - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Endometrial Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Endometrial Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acceleron Pharma, Inc. - Aeterna Zentaris Inc. - Ariad Pharmaceuticals, Inc. - Arno Therapeutics, Inc. - ArQule, Inc. - AstraZeneca Plc - AVEO Pharmaceuticals, Inc. - BioMarin Pharmaceutical Inc. - Boehringer Ingelheim GmbH - Critical Outcome Technologies Inc. - Daiichi Sankyo Company, Limited - Eisai Co., Ltd. - Esperance Pharmaceuticals, Inc. - Exelixis, Inc. - Farmsintez - Galena Biopharma, Inc. - Genentech, Inc. - Genmab A/S - GlaxoSmithKline Plc - Gradalis Inc. - ImmunoGen, Inc. - Incyte Corporation - Karyopharm Therapeutics, Inc. - Merck & Co., Inc. - Merck KGaA - Millennium Pharmaceuticals, Inc. - Novartis AG - OncoHoldings, Inc. - Oncothyreon Inc. - Otsuka Holdings Co., Ltd. - Pharma Mar, S.A. - Puma Biotechnology, Inc. - Sanofi - Scancell Holdings Plc - Shenogen Pharma Group Ltd. Drug Profiles - (ponatinib hydrochloride ridaforolimus) - ???Pb-TCMC-Trastuzumab - AEZS-125 - afuresertib hydrochloride trametinib dimethyl sulfoxide - ARQ-092 - AV-203 - AZD-2014 - AZD-5363 - buparlisib hydrochloride - cabozantinib s-malate - cancer vaccine - Cell Therapy for Oncology - CLR-457 - COTI-2 - cridanimod - dalantercept - EP-200 - epacadostat - everolimus - FROST-450 - GALE-301 - GDC-0927 - GSK-2636771 - HO-3867 - HuMax-TF-ADC - INCB-54828 - lenvatinib - lurbinectedin - mirvetuximab soravtansine - MK-2206 - Modi-1 - Monoclonal Antibody to Inhibit L1CAM for Ovarian and Endometrial Cancer - neratinib - nintedanib - onapristone ER For more information visit http://www.researchandmarkets.com/research/ps...ndometrial
BMRN: 148.05 (+4.05), ARQL: 1.81 (-0.01), GALE: 1.67 (-0.03), EXEL: 5.88 (-0.43), XLRN: 31.50 (-0.68), INCY: 113.21 (-1.21), IMGN: 18.15 (-0.77), GSK: 42.00 (-0.30), ONTY: 3.60 (-0.03), AZN: 66.55 (-0.67), MRK: 58.07 (-0.06), AVEO: 1.61 (+0.01), PBYI: 98.75 (-1.25), KPTI: 22.95 (-0.26), NVS: 103.05 (+1.75)
Market's Not in the Mood to Move
at The Street - Wed Jul 15, 3:24PM CDT
Attention turns to earnings and away from Greece, Fed.
SGYP: 8.42 (-0.14), BLUE: 163.54 (+1.54), AMBA: 122.99 (+0.49), NFLX: 110.10 (-1.40), EYES: 14.41 (+0.04), AMZN: 482.18 (-6.09), ZIOP: 12.59 (-0.19), LNKD: 224.10 (-0.70), FB: 95.44 (-1.60), RCPT: 228.27 (-0.13), LBIO: 9.47 (-0.42), INTC: 28.59 (-0.01), ONTY: 3.60 (-0.03), CELG: 139.01 (+0.75)
Market Shrugs Off Yellen
at The Street - Wed Jul 15, 12:25PM CDT
She didn't say anything to spook the market, but didn't say anything bullish either.
SGYP: 8.42 (-0.14), BLUE: 163.54 (+1.54), AMBA: 122.99 (+0.49), NFLX: 110.10 (-1.40), EYES: 14.41 (+0.04), AMZN: 482.18 (-6.09), ZIOP: 12.59 (-0.19), LNKD: 224.10 (-0.70), FB: 95.44 (-1.60), RCPT: 228.27 (-0.13), LBIO: 9.47 (-0.42), INTC: 28.59 (-0.01), ONTY: 3.60 (-0.03), CELG: 139.01 (+0.75)
An Excuse for a Little Profit-Taking
at The Street - Wed Jul 15, 9:25AM CDT
The market needs some consolidation after a four-day run.
SGYP: 8.42 (-0.14), BLUE: 163.54 (+1.54), AMBA: 122.99 (+0.49), NFLX: 110.10 (-1.40), EYES: 14.41 (+0.04), AMZN: 482.18 (-6.09), ZIOP: 12.59 (-0.19), LNKD: 224.10 (-0.70), FB: 95.44 (-1.60), RCPT: 228.27 (-0.13), LBIO: 9.47 (-0.42), INTC: 28.59 (-0.01), ONTY: 3.60 (-0.03), CELG: 139.01 (+0.75)
Active Equities to Watch in the Biotechnology Industry -- Prima Biomed, Oncothyreon, Opko Health, ImmunoCellular Therapeutics, and Adaptimmune Therapeutics
PR Newswire - Wed Jul 15, 8:00AM CDT
Equity Research Institute has initiated coverage on the following equities: Prima Biomed Ltd (NASDAQ: PBMD), Oncothyreon Inc. (NASDAQ: ONTY), Opko Health Inc. (NYSE: OPK), ImmunoCellular Therapeutics Ltd (AMEX: IMUC), and Adaptimmune Therapeutics PLC (NASDAQ: ADAP). Free research report on Prima Biomed can be accessed at https://www.EquityResearchInstitute.com/reports?keyword=PBMD On Tuesday, July 14, 2015, the NASDAQ Composite ended at 5,104.89, up 0.66%, the Dow Jones Industrial Average advanced 0.42%, to finish the day at 18,053.58, and the S&P 500 closed at 2,108.95, up 0.45%. The gains were broad based as seven out of nine sectors ended the session in positive. Register for your complimentary reports at the links given below.
PBMD: 1.30 (+0.02), OPK: 17.21 (+0.45), ADAP: 16.59 (-1.08), IMUC: 0.52 (+0.01), ONTY: 3.60 (-0.03)
Market Advances by Playing Small Ball
at The Street - Tue Jun 23, 3:18PM CDT
Not too exciting, but bulls keep chugging along.
AMBA: 122.99 (+0.49), TSLA: 267.20 (-0.67), AMZN: 482.18 (-6.09), EYES: 14.41 (+0.04), FMSA: 5.96 (-0.16), FB: 95.44 (-1.60), EHIC: 12.04 (+0.04), IWM: 123.57 (-1.38), ONTY: 3.60 (-0.03)
Waiting for the Word From Greece
at The Street - Tue Jun 23, 12:32PM CDT
Until something concrete comes out of Greece, don't expect much market action.
AMBA: 122.99 (+0.49), EYES: 14.41 (+0.04), FMSA: 5.96 (-0.16), EHIC: 12.04 (+0.04), IWM: 123.57 (-1.38), ONTY: 3.60 (-0.03)
A Tough Market to Chase
at The Street - Tue Jun 23, 9:50AM CDT
Traders just need a few good movers to feel good about the action.
AMBA: 122.99 (+0.49), EYES: 14.41 (+0.04), FMSA: 5.96 (-0.16), EHIC: 12.04 (+0.04), IWM: 123.57 (-1.38), ONTY: 3.60 (-0.03)
The Trend Says It's a Very Friendly Market
at The Street - Thu Jun 18, 3:26PM CDT
You can find flaws with it, but there isn't money to be gained by fighting its strength.
SGYP: 8.42 (-0.14), EYES: 14.41 (+0.04), FMSA: 5.96 (-0.16), CYBR: 61.72 (+4.22), CCXI: 8.40 (-0.30), EDU: 23.20 (+0.35), MOMO: 16.00 (-0.20), ONTY: 3.60 (-0.03)
Putting Cash to Work
at The Street - Thu Jun 18, 12:33PM CDT
It's the only thing that matters right now.
SGYP: 8.42 (-0.14), EYES: 14.41 (+0.04), FMSA: 5.96 (-0.16), CYBR: 61.72 (+4.22), CCXI: 8.40 (-0.30), EDU: 23.20 (+0.35), MOMO: 16.00 (-0.20), ONTY: 3.60 (-0.03)
Spend Your Energy Finding New Buys
at The Street - Thu Jun 18, 9:35AM CDT
Forget about the macro environment; it's business as usual.
SGYP: 8.42 (-0.14), EYES: 14.41 (+0.04), FMSA: 5.96 (-0.16), CYBR: 61.72 (+4.22), CCXI: 8.40 (-0.30), EDU: 23.20 (+0.35), MOMO: 16.00 (-0.20), ONTY: 3.60 (-0.03)
It's Hard for Market to Make Progress
at The Street - Tue Jun 09, 3:21PM CDT
Stocks bounce back but can't gain traction.
AMBA: 122.99 (+0.49), NFLX: 110.10 (-1.40), EYES: 14.41 (+0.04), DSI: 77.42 (-0.48), AZPN: 44.33 (-0.57), LLY: 86.76 (+0.38), ONTY: 3.60 (-0.03), OHGI: 2.50 (-0.06)
Dip Buying Could Spur Ugly Repercussions
at The Street - Tue Jun 09, 1:25PM CDT
The short-terms aren't worrying about that right now.
EYES: 14.41 (+0.04), DSI: 77.42 (-0.48), AZPN: 44.33 (-0.57), ONTY: 3.60 (-0.03), OHGI: 2.50 (-0.06)
ASCO Event Analyzer - 2015's Winners And Losers
EP Vantage - Seeking Alpha - Thu Jun 04, 1:42PM CDT
Neither Bristol-Myers Squibb (NYSE: BMY ) nor Puma Biotechnology (NYSE: PBYI ) can be scored numerically as the biggest loser coming out of ASCO, but in terms of sentiment, they were neck-and-neck for that title. Both took heavy losses after...
RXDX: 15.60 (-0.71), CLLS: 36.48 (-0.61), CALA: 8.06 (-0.32), IMGN: 18.15 (-0.77), JUNO: 51.65 (-0.12), CTIC: 1.92 (+0.01), BMY: 68.24 (-1.13), ONTY: 3.60 (-0.03), PBYI: 98.75 (-1.25)
Top-Performing Biotech and Drug Stocks During ASCO '15
at The Street - Thu Jun 04, 6:49AM CDT
Between May 12 and June 3, Oncothyreon's stock price rose 183%, best among all the companies presenting cancer drug research at the American Society of Clinical Oncology (ASCO) annual meeting.
RXDX: 15.60 (-0.71), IMGN: 18.15 (-0.77), ONTY: 3.60 (-0.03), PBYI: 98.75 (-1.25)
Dollar General and Delta are big market movers
AP - Tue Jun 02, 3:26PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Tuesday on the New York Stock Exchange and the Nasdaq Stock Market:
DAL: 45.16 (-0.06), ALTR: 49.43 (+0.01), CDTI: 1.80 (+0.01), IMGN: 18.15 (-0.77), HPT: 28.08 (-0.81), BMY: 68.24 (-1.13), ONTY: 3.60 (-0.03), PVH: 114.65 (-0.45), TAOM: 3.16 (unch), APO: 20.70 (-0.51), CBRL: 150.00 (-0.93), DG: 79.82 (-0.59), CTRP: 75.15 (+0.97), ZION: 31.59 (-0.34), TA: 16.00 (-0.23)
My Advice For Young Traders To Successfully Navigate The Market
Brian Nichols - at Seeking Alpha - Tue Jun 02, 9:30AM CDT
ACAD: 49.32 (-0.44), IBM: 161.73 (+1.38), S: 3.67 (-0.14), PG: 80.70 (-0.13), ONTY: 3.60 (-0.03), XPO: 44.11 (-1.96), RAD: 8.79 (-0.04)
Oncothyreon Inc (ONTY) in Focus: Stock Surges 15.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jun 02, 8:21AM CDT
Oncothyreon Inc (ONTY) was a big mover last session, as the company saw its shares surge nearly 16% on the day.
ONTY: 3.60 (-0.03)
Oncothyreon Rises 15.79% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Mon Jun 01, 4:30PM CDT
Oncothyreon (NASDAQ:ONTY) traded in a range yesterday that spanned from a low of $3.78 to a high of $4.69. Yesterday, the shares gained 15.8%, which took the trading range above the 3-day high of $3.66 on volume of 38.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ONTY: 3.60 (-0.03)
Why Shares of Oncothyreon Inc. Shot Up Today
Brian Feroldi, The Motley Fool - Motley Fool - Mon Jun 01, 12:31PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Oncothyreon Inc , a biopharmaceutical...
ONTY: 3.60 (-0.03)
